Abstract
Dysfunction of central respiratory CO2/H+ chemosensitivity is a pivotal factor that elicits deep hypoventilation in patients suffering from central hypoventilation syndromes. No pharmacological treatment is currently available. The progestin desogestrel has been suggested to allow recovery of respiratory response to CO2/H+ in patients suffering from central hypoventilation, but except the fact that supramedullary regions may be involved, mechanisms are still unknown. Here, we tested in neonates whether orexin systems contribute to desogestrel’s central effects on respiratory function. Using isolated ex vivo central nervous system preparations from newborn rats, we show orexin and almorexant, an antagonist of orexin receptors, supressed strengthening of the increase in respiratory frequency induced by prolonged metabolic acidosis under exposure to etonogestrel, the active metabolite of desogestrel. In parallel, almorexant suppressed the increase and enhanced increase in c-fos expression in respiratory-related brainstem structures induced by etonogestrel. These results suggest orexin signalisation is a key component of acidosis reinforcement of respiratory drive by etonogestrel in neonates. Although stage of development used is different as that for progestin clinical observations, presents results provide clues about conditions under which desogestrel or etonogestrel may enhance ventilation in patients suffering from central hypoventilation syndromes.
Introduction
Elaboration of a central respiratory drive (CRD) able to match both metabolic demand for O2 and clearance of CO2 relies on central and peripheral structures that generate, integrate, encode, and convey relevant information from the entire body (). Central respiratory chemosensitivity refers to ability of cellular and molecular sensors to detect CO2/H+ variations within brain and initiate appropriate adjustments in ventilation (). The paired-like homeobox 2b (phox2b)-expressing neurons of retrotrapezoid nucleus (RTN) are considered as an important site of CO2/H+ chemosensitivity, especially during the neonatal period (; ). Additionally, there is a general agreement that other neuronal structures, distributed along brainstem and diencephalon contribute to the respiratory response to CO2/H+ challenges (; ; ).
Central hypoventilation syndromes (CHS) are neurorespiratory diseases that result from dysfunction of sensory receptors, respiratory rhythm generators, or other central respiratory structures (). Among these diseases, congenital central hypoventilation syndrome (CCHS) is the best documented. CCHS is a life-threatening sleep-related hypoventilation syndrome associated with an absent or blunted respiratory response to CO2/H+ (Weese-Mayer et al., 2010). The PHOX2B gene is the disease-defining gene for CCHS (). Loss of respiratory response to CO2/H+ is caused, at least partially, by dysfunction of CO2/H+ chemosensitive PHOX2B-positive neurons of the RTN (; ). No pharmacological treatment for CCHS is available, but a serendipitous finding revealed two adult women with CCHS recovered CO2/H+ chemosensitivity concomitant with oral consumption for contraceptive purpose of desogestrel, a potent synthetic progestin belonging to gonane family (; ). Progesterone and synthetic progestins exert a stimulatory effect on respiratory adaptation to gas challenges and baseline respiratory drive in both humans and animal models (, ; ; ). It has thus been suggested desogestrel may have been involved in recovery of CO2/H+ chemosensitivity in CCHS. However, this recovery may not be systematic, as suggested by the non-improvement of respiratory response to CO2/H+ observed in a CCHS patient deliberately given desogestrel (). This discrepancy may rely on idiosyncrasy such as integrity or functioning of one or more central structures. This possibility is supported by the fact that some CCHS patients present alterations in certain central structures that have been suggested in connection with hypoxic episodes (). This context highlights the pressing necessity to elucidate complex mechanisms involved in this gonane progestin effect.
We hypothesized desogestrel, or rather its biologically active metabolite 3-ketodesogestrel (etonogestrel, ETO) (), is able to induce the recovery of CO2/H+ chemosensitivity in some CCHS patients by activating, or enhancing activation, of CO2/H+ sensitive central structures still functional in CCHS patients. Elucidating a physiological basis that underlies recovery of ETO-induced CO2/H+ chemosensitivity is a crucial prerequisite to further evaluate conditions under which it could constitute a therapeutic track for the treatment of CCHS and even CHS in general. In a first exploratory study, we demonstrated acute exposure to ETO potentiates an increase in respiratory frequency (fR) induced by metabolic acidosis through a mechanism involving supramedullary encephalic regions but involved cell population(s) which remain unknown ().
The present study was designed to decipher central mechanisms implicated in strengthening of respiratory response to metabolic acidosis induced by ETO. First, we demonstrate the diencephalon is essential to enhancement of respiratory response to prolonged metabolic acidosis by the progestin in ex vivo central nervous system (CNS) preparations from newborn rats. Second, pattern of c-fos expression, an effective marker of neuronal activation, revealed strengthening of respiratory responses to prolonged metabolic acidosis by ETO is associated with activation or enhanced activation of brainstem respiratory structures. Finally, we demonstrate diencephalic orexin neurons constitute a key neuronal population in the effect of ETO, because blocking orexin signaling resulted in loss of both strengthening of respiratory response to prolonged metabolic acidosis and activation or enhanced activation of brainstem respiratory structures, except medullary raphe nuclei.
Materials and Methods
Experiments were performed on both male and female newborn Sprague-Dawley rats (0–3 days old, 8.1 ± 0.06 g (mean ± standard error of the mean), Janvier Labs; Le Genest Saint Isle, France) in accordance with Directive 2010/63/EU of the European Parliament and of the Council of 22 September, 2010 and French law (2013/118). All protocols were approved by Charles Darwin Ethics Committee for Animal Experimentation (Ce5/2011/05; APAFIS#2210-2015100812195835v2).
Drugs
The following drugs were used: dimethyl sulfoxide (DMSO, Sigma-Aldrich, Saint-Quentin Fallavier, France), ETO (3-ketodesogestrel, Sigma-Aldrich, Saint-Quentin Fallavier, France) prepared in DMSO, orexin A (O6012, Sigma-Aldrich, Saint-Quentin-Fallavier, France) and almorexant (ACT-078573, (2R) - 2 - {(1S) - 6,7 – dimethoxy - 1 - [2 - (4 - trifluoromethylphenyl) - ethyl] - 3,4 – dihydro - 1Hisoquinolin-2-yl} - N-methyl – 2 - phenyl-acetamide), both prepared in saline.
Ex vivo Preparations of Isolated Central Nervous System
Medullary-spinal cord (MS, n = 35), ponto-medullary-spinal cord (PMS, n = 30), brainstem-spinal cord (BS, n = 29), and diencephalon-brainstem-spinal cord (DBS, n = 257) ex vivo preparations were isolated under deep cold anesthesia by immersion in ice water (), as previously described (; ; ). In all cases, a caudal section was made between the seventh and eighth cervical spinal nerve roots. Among the various types of preparations, the level of the rostral section differed: at the level of the anterior inferior cerebellar arteries just caudal to the VIII cranial nerve exit points for MS preparations, rostral to the fifth cranial nerves at the level of the superior cerebellar arteries and caudal edge of the inferior colliculi for PMS preparations, at the level of the intersection between the posterior cerebral and posterior communicating arteries for BS preparations, and at the level of the rostral extremity of the optic chiasm for DBS preparations.
Preparations were superfused with aCSF (in mM: 129 NaCl, 3.35 KCl, 1.15 MgCl2, 0.58 NaH2PO4, 30 D-glucose, 1.26 CaCl2, and NaHCO3 at various concentrations depending on the experimental condition ()) maintained at 26 ± 1°C, saturated with O2, and adjusted to the appropriate pH by bubbling with 95% O2 and 5% CO2. As molecular detectors sensing H+ and CO2 changes are described as sensitive to an increased concentration of H+, we performed pH variation of aCSF to mimic physiological consequences of an increase in CO2 (; ; ; ). It should be noted, however, that future experiments carried out under conditions of acidosis induced by a rise in CO2 could reveal additional mechanisms to those observed in the study. Normal pH-aCSF (pH 7.4) and metabolic acidosis-aCSF (pH 7.23) differed in terms of NaHCO3 concentration (21 and 15 mM, respectively) (; ; ; ). Electrical activity of a fourth cervical ventral nerve root (C4) was recorded using a suction electrode, filtered (300–1000 Hz), amplified (×10000; Differential AC Amplifier Model 1700; A-M systems), integrated (time constant 100 ms), and digitized through a PowerLab 4SP, with a sampling frequency of 2500 Hz, and visualized and analyzed using LabChart 7.2 data acquisition and analysis software (ADInstruments, Castle Hill, Australia). As previously reported, fR was defined as the burst frequency recorded from C4 for 1 min (burst⋅min–1) (; ; ). We did not observe any qualitative changes in integrated C4 burst activity, which was regarded as an index of inspiratory activity, in a first set of experiments, consistent with previous observations (; ). We thus focussed our analysis on fR.
Experimental Protocols
After surgery, all preparations were left to stabilize for 30 min in normal pH-aCSF. Baseline values were defined as mean value during the last 10 min of stabilization period. After that, a given preparation was only exposed to a given pharmacological protocol described in the following paragraphs. In agreement with previous reports concerning ETO or other steroids respiratory effect on newborn rodent less than 4 days old, we pooled data obtained from male and female ex vivo preparations (; ; ).
Determination of the Effect of Etonogestrel on Respiratory Response to Prolonged Metabolic Acidosis of ex vivo Preparations
After stabilization, preparations were superfused for 15 min with normal pH-aCSF, without drugs (MS preparation, n = 10; PMS preparations, n = 10; BS preparations, n = 10 and DBS preparations, n = 9) or supplemented with either DMSO (at 0.01%, MS preparation, n = 16; PMS preparations, n = 10; BS preparations, n = 9 and DBS preparations, n = 13) or ETO in 0.01% DMSO at 5⋅10–2 μM (DBS preparation, n = 10), 5⋅10–1 μM (MS preparation, n = 9; PMS preparations, n = 10; BS preparations, n = 10 and DBS preparations, n = 13), 1 μM (DBS preparations, n = 9) or 2 μM (DBS preparations, n = 12). Mean fR value obtained during the last 5 min of this period was called pre-metabolic acidosis value. Then, preparations were superfused with metabolic acidosis-aCSF without drugs or supplemented with either DMSO or ETO for 30 min. Calculated mean fR during metabolic acidosis exposure was called metabolic acidosis value and was expressed relative to pre-metabolic acidosis value.
As a control, preparations were superfused, after stabilization, with either DMSO (0.01%, n = 12) or 5⋅10–1 μM ETO (n = 24) in normal pH condition for 30 min.
Determination of the Potential Involvement of Orexin Systems in the Effect of Etonogestrel on Respiratory Response to Prolonged Metabolic Acidosis
Determination of concentrations of orexin and almorexant, an OX1R and OX2R antagonist
The effect of orexin on fR at various concentrations on DBS preparations was analyzed to determine both orexin concentration for observing an effect on the central respiratory drive in these ex vivo preparations as previously reported on more reduced ex vivo preparations (; ) and concentration of antagonist (almorexant) that is necessary and sufficient to suppress the effect of orexin. Based on previous studies, orexin A was applied at 5⋅10–4 μM (n = 6), 10–4 μM (n = 6), 10–3 μM (n = 10), 10–2 μM (n = 11) and 10–1 μM (n = 5) (; ). fR was measured during 1 min after 15 min of exposure and expressed relative to baseline values (; ).
We examined the effect of 5⋅10–2 μM (n = 8), 5⋅10–1 μM (n = 7), and 5 μM (n = 9) almorexant on fR of DBS preparations at normal pH, based on the literature (). The effect on fR was assessed by comparing fR during 1 min after 15 min of exposure to baseline values.
On the basis of the results obtained in the two series which have just been described, we applied almorexant and orexin A (10–2 μM, n = 8) together to DBS preparations to determine whether 5⋅10–2 μM almorexant completely blocked orexin signaling. After stabilization, preparations were preincubated with normal pH-aCSF containing almorexant for 15 min before being exposed to normal pH-aCSF containing both almorexant and orexin A for 15 min. The effect of orexin A exposure in the presence of almorexant was assessed by comparing fR calculated over the last min of period of co-application to both baseline values and values obtained under orexin A alone.
Analysis of the effect of etonogestrel on the increase in fR induced by prolonged metabolic acidosis in the presence of orexin or almorexant
We evaluated the effect of ETO on respiratory response to prolonged metabolic acidosis under antagonization of orexin signaling by co-applying 5⋅10–2 μM almorexant and DMSO (n = 13) and 5⋅10–2 μM almorexant and 5⋅10–1 μM ETO (n = 10). After stabilization, DBS preparations were exposed for 15 min to almorexant in normal pH-aCSF. Preparations were then superfused for 15 min with normal pH-aCSF containing almorexant along with either DMSO or ETO. This period was followed by 30 min of superfusion with metabolic acidosis-aCSF containing the same pharmacological agents i.e., almorexant and DMSO or almorexant and ETO. The effect on fR of co-application almorexant/DMSO or almorexant/ETO in normal pH condition was assessed by comparing fR calculated during the last 5 min of these exposures, i.e., pre-metabolic acidosis values, to baseline values. The effect of ETO on prolonged metabolic acidosis response under almorexant was assessed by comparing fR calculated during metabolic acidosis period to pre-metabolic acidosis value.
The effect of orexin alone on the increase in fR induced by prolonged metabolic acidosis was appreciated by applying 10–2 μM orexin (n = 6). After stabilization, DBS preparations were maintained during 30 min under normal pH-aCSF containing 0.01% DMSO and then exposed during 30 min to metabolic acidosis-aCSF containing 10–2 μM orexin with 0.01% DMSO. Prolonged metabolic acidosis response under orexin was assessed by comparing fR calculated during metabolic acidosis period to pre-metabolic acidosis value.
Finally, we evaluated the effect of ETO on respiratory response to prolonged metabolic acidosis under orexin signaling by two experimental designs. First, after stabilization, DBS preparations were maintained during 30 min under normal pH-aCSF containing 0.01% DMSO and then exposed during 30 min to metabolic acidosis-aCSF containing 10–2 μM orexin and 5⋅10–1 μM ETO with 0.01% DMSO (n = 10). Second, after stabilization, DBS preparations were exposed for 15 min to orexin in normal pH-aCSF containing 0.01% DMSO (n = 10). Preparations were then superfused for 15 min with normal pH-aCSF containing orexin and ETO. This period was followed by 30 min of superfusion with metabolic acidosis-aCSF containing orexin and ETO.
Immunohistochemistry
Immunohistochemical Procedures
Immunohistochemical detection of c-FOS was performed on DBS preparations exposed to normal pH or prolonged metabolic acidosis conditions with DMSO alone (n = 4 and n = 4, respectively) or 5⋅10–1 μM ETO (n = 12 and n = 12, respectively) after having undergone the same protocols as those previously described in the relevant paragraphs. Preparations were fixed by immersion in 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) for 48 h at 4°C after exposure to DMSO or 5⋅10–1 μM ETO with or without almorexant. All preparations were left to stabilize for 30 min in normal pH-aCSF after surgery. For preparations not exposed to almorexant, either they were maintained under normal pH conditions with DMSO alone or 5⋅10–1 μM ETO during 30 min or they were superfused with aCSF containing DMSO alone or 5⋅10–1 μM ETO during 15 min under normal pH following by 30 min under metabolic acidosis conditions. For preparations exposed to almorexant, they were exposed for 15 min to almorexant in normal pH-aCSF, then for 15 min with normal pH-aCSF containing almorexant along with either DMSO or 5⋅10–1 μM ETO, and finally, for 30 min with metabolic acidosis-aCSF containing the same pharmacological agents i.e., almorexant and DMSO or almorexant and 5⋅10–1 μM ETO. After immersion in paraformaldehyde solution, preparations were cryoprotected for 72 h in 0.1 M phosphate buffer containing 30% sucrose. Immunohistochemical detection of c-FOS was processed on free-floating coronal sections (40 μm) by incubation with first, a rabbit polyclonal antibody against c-FOS (sc-253; Santa Cruz Biotechnology Inc., CA, United States, 1:10000, in 1% bovine serum albumin, BSA; 48 h, 4°C), second a biotinylated goat anti-rabbit IgG antibody (Vector Laboratories, Burlington, Canada, 1:500; 2 h), and finally an avidin-biotin-peroxidase complex (ABC; Novostain Super ABC kit, Novocastra Laboratories, Newcastle, United Kingdom, 1:250; 1 h). Peroxidase activity was detected using a solution containing 0.02% 3,3′- diaminobenzidine tetrahydrochloride, 0.04% nickel ammonium sulfate and 0.01% H2O2 in 0.05 M Tris–HCl buffer (pH 7.6), which results in a blue/gray chromogen.
Dual detection of c-FOS and orexin A was performed on DBS preparations exposed to prolonged metabolic acidosis conditions under DMSO alone, 5⋅10–1 μM ETO alone, almorexant/DMSO, or almorexant/5⋅10–1 μM ETO to specifically analyse changes in cell activity in orexin neurons. After c-FOS detection, sections were incubated with a goat polyclonal antibody against orexin A (sc-8070, Santa Cruz Biotechnology Inc., CA, United States, 1:2000, in 1% BSA; 48 h, 4°C), with a biotinylated rabbit anti-goat IgG antibody (Vector Laboratories, Burlington, Canada, 1:500; 2 h) and then with ABC (1:250; 1 h). Peroxidase activity was detected with 0.02% 3,3′-diaminobenzidine tetrahydrochloride and 0.01% hydrogen peroxide in 0.05 M Tris–HCl buffer (pH 7.6) resulting in a brown chromogen.
For single or dual detections, control sections were processed in parallel, but with the omission of primary or secondary antibodies. No labeling was observed on control sections.
All sections were mounted in sequential caudo-rostral order on silanized slides, air-dried, and coverslipped with Entellan (VWR, International S.A.S).
Cell Counting
c-FOS and c-FOS/orexin immunolabeled cells were visually counted, by an investigator blinded to the samples under a light microscope (Leica DM 2000; Leica Microsystems, Heidelberg, Germany) at high magnification (×200 or ×400 depending on the immunolabelled density of cells) by varying micrometer of the microscope which was essential for tissue sections of 40 micrometers. Analyzed structures involved in CRD elaboration or adaptation, were localized using standard landmarks (). Microphotographs were captured with a digital camera (Leica DFC450C, Leica Microsystems, Heidelberg, Germany). We counted c-FOS positive cells along medulla oblongata in commissural, medial and ventrolateral parts of the nucleus of the solitary tract (cNTS, mNTS, and vlNTS), in parapyramidal area (PP), at the lateral edge of pyramidal tract, extending from pyramidal decussation to caudal edge of the facial nucleus (), in medullary raphe nuclei i.e., raphe pallidus, obscurus and magnus nuclei (RPa, ROb, and RMg), in RTN (in the ventral medullary surface in ventromedial position under the facial nucleus) (), in pFRG (in the ventral medullary surface in ventrolateral position under the facial nucleus) (), and in ventrolateral reticular nucleus of the medulla (VLM), a neuronal column ventral to nucleus ambiguus, extending from pyramidal decussation to caudal edge of facial nucleus that encompass the preBotC and the A1/C1 group of neurons. In pons, c-FOS positive cells were counted in locus coeruleus (LC), A5 region (A5), lateral subnucleus of parabrachial nucleus (lPB), and medial subnucleus of the parabrachial nucleus/kölliker-fuse nucleus (mPB/KF). In mesencephalon, c-FOS positive cells were counted in dorsal, dorsolateral, lateral and ventrolateral parts of the periaqueductal gray (dPAG, dlPAG, lPAG, and vlPAG). In diencephalon, single-labeled (c-FOS) or double-labeled (c-FOS/orexin) cells were counted in lateral hypothalamic area (LH), posterior hypothalamic area (PH), dorsomedial hypothalamic nucleus (DMH), and perifornical region (PeF). The mean number of c-FOS and c-FOS/orexin positive cells per section were quantified for each structure.
Statistics
Data were analyzed with GraphPad (GraphPad Prism8, San Diego, CA, United States). Normality of data distribution for fR, c-FOS and c-FOS/orexin values was assessed using d’Agostino and Pearson omnibus normality test. Baseline fR are expressed as mean ± standard error of the mean as data distribution is normal. As electrophysiological and histological series include group(s) with a non-normal distribution, all results are expressed as a median and interquartile range [Q1; Q3]. Parametric or non-parametric tests were performed, depending on normality. Within each group, the effect of an experimental condition on fR was assessed using a one-sample t test or a Wilcoxon signed rank test. Comparisons of the effect on fR between two groups were performed using two-tailed unpaired t tests or Mann Whitney tests. To highlight differences induced by experimental conditions between more than two groups, intergroup comparisons of fR or percentage of change of fR were performed using a one-way ANOVA, followed by Bonferroni’s multiple comparison test, or Kruskal-Wallis test followed by Dunn’s or Benjamini, Krieger and Yekutieli’s multiple comparison test. Number of c-FOS positive cells and c-FOS/orexin cells per section were compared between two conditions using one-tailed or two-tailed Mann Whitney tests, depending on stated hypothesis. Differences were considered to be significant if p < 0.05.
Results
Baseline Respiratory Frequency of ex vivo Preparations Used for All Respiratory Drive Analyses
Baseline fR was 7.19 ± 0.21 bursts⋅min–1 for DBS (n = 221), 5.47 ± 0.59 bursts⋅min–1 for BS (n = 29), 4.51 ± 0.50 bursts⋅min–1 for PMS (n = 30), and 8.87 ± 0.30 bursts⋅min–1 for MS (n = 35) preparations. fR of all the 221 DBS preparations, as well as fR of 4 different random selections of DBS preparations among the 221 (7.16 ± 0.60; 7.29 ± 0.62; 7.17 ± 0.55; 7.31 ± 0.67 bursts⋅min–1) was significantly higher than fR of BS (p < 0.04) and PMS (p < 0.001) preparations but significantly lower than that of MS preparations (p < 0.05).
Etonogestrel Strengthens Respiratory Response to Prolonged Metabolic Acidosis in a Small Concentration Range
In response to prolonged metabolic acidosis, DBS preparations superfused without drugs or exposed to DMSO exhibit a similar significant increase in fR (+25.0% [16.6;40.7], p < 0.01 and +29.2% [16.4;46.4], p < 0.0001, respectively at 25–30 min of metabolic acidosis). In preparations exposed to 5⋅10–2 μM, 1 μM, and 2 μM ETO, increase in fR induced by prolonged metabolic acidosis (+41.3% [27.0;54.8], p < 0.001, +58.8% [20.1;102.1.8], p < 0.05, and +16.2% [8.2;44.3], p < 0.05, respectively at 25–30 min of metabolic acidosis) is not significantly different from that observed in preparations exposed to DMSO (Figure 1). In contrast, increase in fR induced by prolonged metabolic acidosis in the presence of 5⋅10–1 μM ETO (+68.2% [57.1;149.3], p < 0.01 at 25–30 min of metabolic acidosis) is significantly greater than that observed in preparations exposed to DMSO (p < 0.01 at 25–30 min of metabolic acidosis) (Figure 1). This strengthening of increase in fR is also significantly greater than that observed for preparations exposed to 5⋅10–2 and 2 μM ETO (p < 0.05 and p < 0.01, respectively at 25–30 min of metabolic acidosis) (Figure 1). Note ETO at 5⋅10–1 μM does not induce a significant increase in fR at normal pH (DMSO: (+6.9% [−26.1;75.9] vs. ETO: +28.7% [15.0;50.0]).
FIGURE 1
In addition to comparison of last 5 min of metabolic acidosis, analysis of fR modifications observed over 30 min of exposure reveals differences in the time required to observe an increase in fR induced by metabolic acidosis (Figure 1). Under DMSO exposure, fR increases significantly from 15–20 min exposure to metabolic acidosis (+20.3% [5.9;33.5], p < 0.05). Under ETO at 5⋅10–2 and 5⋅10–1 μM, fR increases significantly more precociously than without ETO, from the first 5 min of metabolic acidosis (+19.1% [8.8;33.2], p < 0.0005 and +15.8% [8.3;41.9], p < 0.003, respectively). For ETO at 0.05 μM, fR is significantly greater than that observed in preparations exposed to DMSO from the first 15 min (p < 0.05). For ETO at 0.5 μM, fR is significantly greater than that observed in preparations exposed to DMSO throughout metabolic exposure (p < 0.05). Under ETO at 1 μM, fR increases significantly from 10–15 min of metabolic acidosis (+25.0% [5.1;48.4], p < 0.03). Under ETO at 2 μM, fR increases significantly from 25–30 min of metabolic acidosis (+16.2% [8.2;44.3], p < 0.03). For ETO at 1 and 2 μM, fR is not significantly different from that observed under DMSO exposure throughout metabolic exposure.
In light of these results, subsequent experiments involving ETO were performed in the presence of 5⋅10–1 μM, the effective dose of this progestin.
Etonogestrel-Dependant Strengthening of Respiratory Response to Prolonged Metabolic Acidosis Requires Presence of the Diencephalon
Prolonged metabolic acidosis, without drug exposure, induces significant increases in fR in BS (+22.5% [0.0;38.1], p < 0.01), PMS (+15.5% [0.0;21.3], p < 0.05), and MS (+29.2% [1.8;33.3], p < 0.05) preparations at 25–30 min of metabolic acidosis, as in DBS preparations. These increases are equivalent to those observed under DMSO (BS: +27.3% [6.8;52.2], p < 0.05; PMS: +27.0% [12.9;57.1], p < 0.01; MS: +30.9 [14.9;41.0], p < 0.01) at 25–30 min of metabolic acidosis (Figure 2). Comparison of increases in fR for all types of preparations (DBS, BS, PMS, and MS) showed respiratory response to prolonged metabolic acidosis in the presence of DMSO is of same magnitude, irrespective of the rostral extension of preparations (Figure 2). In addition, ETO does not strengthen respiratory response to prolonged metabolic acidosis in preparations lacking diencephalic structures at concentration at which it produces such an effect in DBS preparations (5⋅10–1 μM). Indeed, BS, PMS, and MS preparations displayed significant increases in fR in response to prolonged metabolic acidosis in the presence of ETO (BS: +25.9% [8.1;39.8], p < 0.05; PMS: +47.5% [17.6;83.1], p < 0.05; MS +22.5% [5.9;33.5], p < 0.05) at 25–30 min of metabolic acidosis, which are similar to those observed in their respective control groups exposed to DMSO (Figure 2).
FIGURE 2

Strengthening of respiratory response to prolonged metabolic acidosis by etonogestrel depends on the presence of diencephalon. (A–P) Representative traces illustrating respiratory C4 activity recorded in DBS (A–D), BS (E–H), PMS (I–L), and MS (M–P) preparations, during condition of pre-metabolic acidosis under DMSO (A,E,I,M) or ETO (C,G,K,O) exposure and during condition of prolonged metabolic acidosis under DMSO (B,F,J,N) or ETO (D,H,L,P) exposure. (Q) Column scatter graph with a superimposed box and whisker plot (median [Q1;Q3]) showing percentage of change of fR at 25–30 min of metabolic acidosis under conditions of prolonged metabolic acidosis in the presence of either DMSO or ETO on DBS (n = 13 and n = 13, respectively), BS (n = 9 and n = 10, respectively), PMS (n = 10 and n = 10, respectively), and MS (n = 16 and n = 9, respectively) preparations. ∗Indicates a significant intragroup change (one-sample t test) in fR relative to the values obtained just prior placing under conditions of metabolic acidosis. #Indicates a significant difference (one-way ANOVA followed by Bonferroni’s multiple comparison test) between groups. ∗p < 0.05, ∗∗p < 0.01, ****p < 0.0001, #p < 0.05. ∫C4: integrated activity of the C4 ventral nerve root; C4: electrical activity of the C4 ventral nerve root; ETO: etonogestrel, DBS: diencephalon-brainstem-spinal cord preparation, BS: brainstem-spinal cord preparation, PMS: ponto-medullary-spinal cord preparation, MS: medullary-spinal cord preparation.
Etonogestrel Modifies c-fos Expression Induced by Prolonged Metabolic Acidosis in Central Structures Involved in Elaboration of the Central Respiratory Drive and/or Its Regulation
Etonogestrel Does Not Induce Changes in c-fos Expression in Normal pH Condition
We first quantified c-FOS positive cells in DBS preparations superfused with either DMSO or ETO (5⋅10–1 μM) at normal pH to determine potential ETO-induced changes of cell activity that do not depend on stimulation of metabolic acidosis. There is no significant difference in number of c-FOS-positive cells between DMSO or ETO exposed preparations (Table 1), in accordance with the fact that fR is not significantly modified by ETO at normal pH.
TABLE 1
| Normal pH | Prolonged metabolic acidosis | ||||
| DMSO | ETO | DMSO | ETO | ||
| (n = 4) | (n = 4) | (n = 8) | (n = 8) | ||
| Medulla oblongata | cNTS | 28.2 [21.4;42.4] | 39.0 [18.2;51.0] | 16.7 [12.6;24.0] | 73.3 [55.2;88.3]###,§ |
| vlNTS | 1.5 [0.5;2.5] | 1.6 [1.1;2.4] | 4.5 [4.0;6.2]∗ | 37.5 [25.1;39.3]###,§§ | |
| mNTS | 5.4 [2.2;6.4] | 4.7 [2.5;7.5] | 7.7 [5.0;13.0] | 105.2 [65.7;129.2]###,§§ | |
| ROb | 3.4 [2.1;3.6] | 3.2 [2.9;4.6] | 4.8 [2.0;6.3] | 17.1 [10.0;26.4]##,§§ | |
| RPa | 9.4 [6.1;11.9] | 7.6 [3.7;8.4] | 7.7 [4.7;9.1] | 16.1 [8.0;22.1]#,§ | |
| RMg | 13.9 [11.7;18.9] | 11.8 [10.1;13.6] | 13.4 [9.3;19.9] | 19.6 [13.1;30.8] | |
| PP | 2.9 [1.5;3.7] | 2.7 [1.7;3.1] | 5.6 [5.4;7.1]∗∗ | 4.8 [3.7;5.9]§§ | |
| VLM | 12.6 [11.3;17.4] | 12.5 [11.2;18.2] | 26.0 [21.4;28.8]∗∗ | 46.5 [36.5;89.4]##,§§ | |
| RTN | 16.2 [9.0;18.6] | 14.4 [10.3;18.0] | 22.9 [18.9;26.5]∗ | 23.3 [21.8;25.4]§ | |
| pFRG | 6.2 [2.9;9.5] | 4.3 [3.0;5.5] | 6.8 [5.5;9.2] | 4.6 [3.9;6.6] | |
| Pons | A5 | 15.7 [9.0;21.3] | 14.4 [13.0;16.2] | 16.6 [12.8;19.5] | 22.7 [17.7;38.4]§ |
| LC | 3.2 [1.7;4.2] | 0.9 [0.5;1.6] | 22.5 [9.0;35.8] ∗ | 81.9 [34.8;88.2]#,§§ | |
| lPB | 2.7 [0.6;3.5] | 0.2 [0.0;0.6] | 3.7 [0.3;8.8] | 7.6 [4.8;12.9]§§ | |
| mPB/KF | 0.8 [0.4;1.2] | 1.4 [0.7;1.9] | 11.9 [5.5;16.8] | 19.4 [10.5;22.9]§§ | |
| Mesencephalon | dPAG | 0.2 [0.2;0.5] | 0.3 [0.1;0.5] | 0.2 [0.0;0.7] | 0.9 [0.3;1.5] |
| dlPAG | 0.3 [0.2;1.5] | 0.7 [0.1;6.1] | 0.9 [0.3;4.7] | 0.8 [0.4;1.5] | |
| lPAG | 2.7 [0.9;5.7] | 2.3 [1.7;4.5] | 5.5 [1.6;10.3] | 26.2 [10.8;50.0]# | |
| vlPAG | 1.3 [0.5;2.0] | 1.2 [0.7;2.6] | 6.3 [2.3;10.8]∗ | 25.6 [15.4;33.9]# | |
| Diencephalon | DM | 28.0 [21.2;31.6] | 22.6 [15.1;48.8] | 23.9 [19.6;38.0] | 23.6 [13.9;48.6] |
| LH | 28.9 [21.3;29.5] | 20.2 [16.8;29.9] | 33.9 [29.0;59.7] | 23.8 [17.4;42.5] | |
| PeF | 0.8 [0.4;0.9] | 0.8 [0.3;0.8] | 3.2 [2.1;6.2]∗ | 2.8 [2.5;5.4] | |
| PH | 3.8 [3.7;7.0] | 2.6 [0.9;7.0] | 15.0 [8.8;20.7] | 14.2 [6.5;19.0] | |
c-fos expression in brainstem and diencephalic structures of DBS ex vivo preparations under normal pH and prolonged metabolic acidosis conditions in the presence of either DMSO or etonogestrel.
Values are expressed as median number of c-FOS positive cells per section [Q1;Q3]. Comparison between DMSO and ETO groups under normal pH conditions shows no significant difference. ∗ indicates a significant increase in number of c-FOS positive cells per structure under prolonged metabolic acidosis condition compared to normal pH condition both in the presence of DMSO. # indicates a significant increase in number of c-FOS positive cells per structure under prolonged metabolic acidosis condition in the presence of ETO (5⋅10–1 μM) compared to that in the presence of DMSO. § indicates a significant increase in number of c-FOS positive cells per structure under prolonged metabolic acidosis condition compared to normal pH condition in the presence of ETO (5⋅10–1 μM). ∗p < 0.05, ∗∗p < 0.01, #p < 0.05, ##p < 0.01, ###p < 0.001, §p < 0.05, §§p < 0.01. A5: A5 region, cNTS: commissural part of the nucleus tractus solitarius, dlPAG: dorsolateral part of the periaqueductal gray, DM: dorsomedial hypothalamic nucleus, dPAG: dorsal part of the periaqueductal gray, LC: locus coeruleus, LH: lateral hypothalamic area, lPAG: lateral part of the periaqueductal gray, lPB: lateral subnucleus of the parabrachial nucleus, mNTS: median part of the nucleus tractus solitarius, mPB/KF: medial subnucleus of the parabrachial nucleus/kölliker-fuse nucleus, PeF: perifornical region, pFRG: parafacial respiratory group; PH: posterior hypothalamic area, PP: parapyramidal group, RMg: raphe magnus nucleus, ROb: raphe obscurus nucleus, RPa: raphe pallidus nucleus, RTN: retrotrapezoid nucleus; VLM: ventrolateral medullary reticular nucleus, vlNTS: ventrolateral part of the nucleus tractus solitarius, vlPAG: ventrolateral part of the periaqueductal gray.
Prolonged Metabolic Acidosis Induces an Increase in Number of c-FOS Positive Cells in Absence of Etonogestrel
We next investigated whether prolonged metabolic acidosis stimulated c-fos expression in brainstem and diencephalic structures. Prolonged metabolic acidosis induces a significant increase in number of c-FOS positive cells relative to that at normal pH at the level of the medulla oblongata in vlNTS (p < 0.05), PP (p < 0.01), VLM (p < 0.01) and RTN (p < 0.05), pons in LC (p < 0.05), mesencephalon in vlPAG (p < 0.05), and diencephalon in PeF (p < 0.05) (Table 1).
Etonogestrel Strengthens Metabolic Acidosis-Induced Increase in Number of c-FOS Positive Cells in Some Brainstem Respiratory Structures
Under prolonged metabolic acidosis, exposure of DBS preparations to 5⋅10–1 μM ETO further increases number of c-FOS positive cells at the level of medulla oblongata, in VLM (p < 0.01) and vlNTS (p < 0.001), pons in LC (67.63 ± 10.02 vs. 22.40 ± 7.03, p < 0.05), and mesencephalon in vlPAG (p < 0.05) (Figures 3, 4, and Table 1). Except for vlPAG, this increase in number of c-FOS positive cells under metabolic acidosis between DMSO and ETO parallels with a significant increase in number of c-FOS positive cells under ETO/prolonged metabolic acidosis compared to ETO/normal pH (p < 0.01; Table 2).
FIGURE 3

Etonogestrel increases or enhances increase in prolonged metabolic acidosis-induced c-fos expression in medullary respiratory-related areas. Drawings representing distribution of cells immunoreactive for c-FOS during prolonged metabolic acidosis (black points) in medulla oblongata under DMSO (a) or 5⋅10–1 μM etonogestrel (b) exposure. Photomicrographs illustrating metabolic acidosis-induced c-FOS immunoreactivity under DMSO (c,e,g,i) or etonogestrel (d,f,h,j) exposure in mNTS and vlNTS (c,d), ROb (e,f), RPa (g,h), and VLM (i,j). Scale bar = 100 μm. Abbreviations: ambiguus nucleus (Amb), area postrema (AP), central canal (cc), etonogestrel (ETO), hypoglossal nucleus (XII), inferior olives (IO), median part of the nucleus of the tractus solitarius, (mNTS), parapyramidal group (PP), obscurus (ROb) and pallidus (RPa) raphe nuclei, pyramidal tract (Py), ventrolateral medullary reticular nucleus (VLM), ventrolateral part of the nucleus of the tractus solitarius (vlNTS), and dorsal motor nucleus of vagus (X).
FIGURE 4

Etonogestrel increases or enhances increase in prolonged metabolic acidosis-induced c-fos expression in supra-medullary respiratory-related areas. Drawings representing distribution of cells immunoreactive for c-FOS during prolonged metabolic acidosis (black points) in pons and in mesencephalon under DMSO (A,C) or 5⋅10–1 μM etonogestrel (B,D) exposure. Photomicrographs illustrating metabolic acidosis-induced c-FOS immunoreactivity under DMSO (E,G) or 5⋅10–1 μM etonogestrel (F,H) exposure in LC (E,F), lPAG, and vlPAG (G,H). Scale bar = 100 μm. Abbreviations: A5 region (A5), aqueduct of Sylvius (Aq), dorsolateral part of the periaqueductal gray (dlPAG), dorsomedian part of the periaqueductal gray (dPAG), dorsal raphe nucleus (DR), etonogestrel (ETO), locus coeruleus (LC), lateral part of the periaqueductal gray (lPAG), lateral parabrachial nucleus (lPB), median raphe nucleus (MnR), medial parabrachial nucleus/kölliker-fuse nucleus (mPB/KF), motor trigeminal nucleus (Mo5), superior olives (SO), trapezoid body (TZ), ventrolateral part of the periaqueductal gray (vlPAG), and facial nerve (7n).
TABLE 2
| Prolonged metabolic acidosis | |||
| Almorexant/DMSO | Almorexant/ETO | ||
| (n = 4) | (n = 4) | ||
| Medulla oblongata | cNTS | 29.9 [29.4;33.3] | 29.4 [22.4;40.3] |
| vlNTS | 6.8 [5.1;8.4] | 5.3 [3.4;7.5] | |
| mNTS | 5.2 [4.4;9.2] | 11.6 [7.5;15.8] | |
| ROb | 5.2 [4.4;9.2] | 11.6 [7.5;15.8]# | |
| RPa | 11.5 [9.1;13.5] | 15.5 [14.2;16.2]# | |
| RMg | 21.3 [21.2;22.0] | 20.4 [18.4;25.9] | |
| PP | 7.0 [5.6;8.3] | 4.3 [2.5;7.1] | |
| VLM | 20.9 [20.0;25.9] | 26.8 [24.6;32.5] | |
| RTN | 21.0 [16.4;25.7] | 24.5 [21.8;28.8] | |
| pFRG | 6.9 [4.0;8.9] | 7.5 ([7.0;8.1] | |
| Pons | A5 | 11.1 [9.0;15.1] | 15.7 [13.4;22.4] |
| LC | 1.6 [0.4;3.0] | 8.5 [3.0;13.5] | |
| lPB | 1.8 [0.4;14.2] | 9.9 [4.6;13.6] | |
| mPB/KF | 6.2 [0.6;10.4] | 10.2 [5.0;16.4] | |
| Mesencephalon | dPAG | 1.0 [0.7;1.8] | 0.8 [0.6;1.1] |
| dlPAG | 0.8 [0.5;0.9] | 1.1 [0.6;1.7] | |
| lPAG | 2.1 [1.5;2.8] | 2.7 [2.2;3.5] | |
| vlPAG | 2.5 [2.3;3.4] | 4.6 [3.0;5.8] | |
| Diencephalon | DM | 23.7 [12.6;40.6] | 19.1 [13.6;20.2] |
| LH | 31.3 [15.3;36.4] | 19.7 [14.2;28.5] | |
| PeF | 1.8 [1.2;3.3] | 2.0 [1.1;2.9] | |
| PH | 9.4 [3.7;16.3] | 4.4 [3.3;5.9] | |
c-fos expression in brainstem and diencephalic structures of DBS ex vivo preparations under prolonged metabolic acidosis condition in the presence of almorexant/DMSO and almorexant/etonogestrel.
Values are expressed as median number of c-FOS positive cells per section [Q1;Q3]. # indicates a significant increase in number of c-FOS positive cells under almorexant (5⋅10–2 μM)/ETO (5⋅10–1 μM) exposure compared to almorexant/DMSO exposure. #p < 0.05. A5: A5 region, cNTS: commissural part of the nucleus tractus solitarius, dlPAG: dorsolateral part of the periaqueductal gray, DM: dorsomedial hypothalamic nucleus, dPAG: dorsal part of the periaqueductal gray, LC: locus coeruleus, LH: lateral hypothalamic area, lPAG: lateral part of the periaqueductal gray, lPB: lateral subnucleus of the parabrachial nucleus, mNTS: median part of the nucleus tractus solitarius, mPB/KF: medial subnucleus of the parabrachial nucleus/kölliker-fuse nucleus, PeF: perifornical region, pFRG: parafacial respiratory group; PH: posterior hypothalamic area, PP: parapyramidal group, RMg: raphe magnus nucleus, ROb: raphe obscurus nucleus, RPa: raphe pallidus nucleus, RTN: retrotrapezoid nucleus; VLM: ventrolateral medullary reticular nucleus, vlNTS: ventrolateral part of the nucleus tractus solitarius, vlPAG: ventrolateral part of the periaqueductal gray.
Etonogestrel Induces Increases in Number of c-FOS-Positive Cells Under Prolonged Metabolic Acidosis in Central Structures Not Activated Without Progestin
Exposure to ETO induces a significant increase in number of c-FOS positive cells under prolonged metabolic acidosis relative to DMSO exposure in structures not activated by prolonged metabolic acidosis without progestin at the level of medulla oblongata in cNTS (p < 0.001), mNTS (p < 0.001), RPa (p < 0.05), and ROb (p < 0.01), pons in LC (p < 0.05), mesencephalon in lPAG (p < 0.05) and vlPAG (p < 0.05) (Figures 3, 4 and Table 1). For all these structures, this increase in number of c-FOS positive cells under metabolic acidosis between DMSO and ETO parallels with a significant increase in number of c-FOS positive cells under ETO/prolonged metabolic acidosis compared to ETO/normal pH (p < 0.05 or 0.01; Table 2).
Additionally, we observed a significant increase in number of c-FOS positive cells under ETO/prolonged metabolic acidosis compared to ETO/normal pH in 2 structures not significantly different between DMSO and ETO under metabolic acidosis at the level of the medulla oblongata in RTN (p < 0.05), and pons in A5 (p < 0.05).
Etonogestrel Increases Number of c-FOS Positive Orexin Neurons Under Prolonged Metabolic Acidosis
Analysis of the effect of ETO under prolonged metabolic acidosis on various types of ex vivo preparations suggests its effect on respiratory response requires the presence of diencephalon. Surprisingly, as stated above, we do not observe any change in number of c-FOS positive cells induced by ETO in caudal hypothalamus, which encompasses DMH, LH, PH, and PeF (Table 1). Orexin neurons are CO2/H+ chemosensitive (Williams et al., 2007;
FIGURE 5

Prolonged metabolic acidosis induced c-fos expression was increased in orexin neurons of caudal hypothalamus by etonogestrel. Drawings showing distribution of cells immunoreactive for c-FOS (black points) and both c-FOS and orexin (white points) in caudal hypothalamus under DMSO (a,c) or 5⋅10–1 μM etonogestrel (b,d) exposure. Drawings in panels (c,d) represent an enlargement of black rectangle in panels (a,b), respectively. Photomicrographs illustrating metabolic acidosis-induced c-FOS (blue-gray) and orexin (brown) immunoreactivities under DMSO (e) and 5⋅10–1 μM etonogestrel (f) exposure. Photomicrographs correspond to regions outlined by black rectangles in panel (c) for (e) and in panel (d) for (f). Scale bar = 100 μm. Abbreviation: dorsomedian hypothalamic nucleus (DMH), etonogestrel (ETO), fornix (f), lateral hypothalamic area (LH), mamillothalamic tract (mt), optic tract (opt), perifornical area (PeF), posterior hypothalamic area (PH), and third ventricule (V3).
Orexin Systems Are Involved in Strengthening of Respiratory Response to Prolonged Metabolic Acidosis Induced by Etonogestrel
We further analyzed the effect of ETO in the presence of almorexant, a specific antagonist of orexin receptors 1 and 2 (OX1R and OX2R, respectively), to further investigate the involvement of orexin systems. We first evaluated orexin’s influence on fR to determine the concentration of almorexant sufficient and necessary to abolish orexin respiratory influence.
Orexin A Induces an Increase in fR in DBS Preparations at Normal pH
Diencephalon-brainstem-spinal cord preparations show a significant increase in fR when exposed to 10–3 μM (+47.0% [28.4;71.8], p < 0.05) and 10–2 μM (+ 59.4% [31.7;63.8], p < 0.05) orexin A (Figure 6A). In contrast, 10–4 μM (+11.3% [−3.9;26.4]), 5⋅10–4 μM (+7.1% [−15.6;22.3]), and 10–1 μM (+9.1%% [7.4;21.5]) orexin A does not induce an increase in fR (Figure 6A). We selected 10–2 μM orexin A for subsequent experiments to ensure its full effect.
FIGURE 6

Orexin systems are involved in strengthening of respiratory response to prolonged metabolic acidosis by etonogestrel. Column scatter graph with a superimposed box and whisker plot (median [Q1;Q3]) illustrating percentage of change of fR at 25–30 min of metabolic acidosis at normal pH (A) in the presence of orexin at 10–4 (n = 6), 5⋅10–4 (n = 6), 10–3 (n = 10), 10–2 (n = 11), and 10–1 μM (n = 5) or (B) in the presence of either orexin alone (10–2 μM, n = 11) or almorexant (10–2 μM) and orexin (10–2 μM) together (n = 8). ∗ Indicates a significant change [Wilcoxon signed rank test (A) and one-sample t test (B)] in mean fR relative to baseline values. # Indicates a significant difference [unpaired t-test (B)] between exposure to orexin alone and co-exposure to almorexant and orexin together. (C) histogram showing mean percentage change of fR under conditions of prolonged metabolic acidosis in the presence of either DMSO or ETO alone (DMSO n = 13 and ETO n = 13) or with almorexant (DMSO n = 13 and ETO n = 10). ∗ Indicates a significant intragroup change (one-sample t test) in mean fR relative to values obtained just prior to placing under conditions of metabolic acidosis. # Indicates a significant difference (one-way ANOVA followed by Bonferroni’s multiple comparison test) between groups. Data are expressed as the mean ± SEM.∗p < 0.05, ∗∗p < 0.01, ****p < 0.0001, ##p < 0.01, ###p < 0.001. (D–K) Representative traces illustrating respiratory C4 activity recorded in DBS preparations during pre-metabolic acidosis under DMSO (D), ETO (F), DMSO/almorexant (H), or ETO/almorexant (J) exposure and during prolonged metabolic acidosis under DMSO (E), ETO (G), DMSO/almorexant (I), or ETO/almorexant (K) exposure. (L) Column scatter graph with a superimposed box and whisker plot (median [Q1;Q3]) showing percentage change of fR at 25–30 min of metabolic acidosis under conditions of prolonged metabolic acidosis in the presence of either DMSO or ETO alone (DMSO n = 13 and ETO n = 13) or with orexin (DMSO n = 6 and ETO n = 10). ∗ Indicates a significant intragroup change (Wilcoxon test) in mean fR relative to the values obtained just prior to placing under conditions of metabolic acidosis. # Indicates a significant difference (Kruskal-Wallis test followed by Dunn’s multiple comparisons test) between groups. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, #p < 0.05. ∫C4: integrated activity of the C4 ventral nerve root; C4: electrical activity of the C4 ventral nerve root; ETO: etonogestrel.
Almorexant Completely Blocks Orexin A-Induced Increase in fR of DBS Preparations at Normal pH
Exposing DBS preparations to 5⋅10–2 μM almorexant does not induce a change of fR (+10.9% [−7.7;21.8]). At higher concentrations, almorexant exposure significantly increases fR (5⋅10–1 μM: +15.4% [3.0;37.5], p < 0.05; and 5 μM: +39.9% [5.2;54.5], p < 0.01). In light of these results and the results of others (
Under antagonization of OX1R and OX2R by almorexant (5⋅10–2 μM), 10–2 μM orexin A fails to induce significant increase in fR observed in absence of antagonist (+6.3% [−8.2;12.0] vs. +59.4% [31.7;63.8], p < 0.001, respectively) (Figure 6B). Exposing DBS preparations to 5⋅10–2 μM almorexant was thus considered to be sufficient to abolish the respiratory effect of orexin A.
Blocking Orexin Systems by Almorexant Completely Suppresses Strengthening of Respiratory Response to Prolonged Metabolic Acidosis Induced by Etonogestrel
Diencephalon-brainstem-spinal cord preparations superfused with normal pH artificial cerebrospinal fluid (aCSF), containing either almorexant/DMSO or almorexant/5⋅10–1 μM ETO, display no change in their fR (+11.3% [−2.6;27.4] and +1.6% [−8.4;14.2], respectively).
In the presence of DMSO, almorexant does not change the increase in fR induced by prolonged metabolic acidosis (Figures 6D,E,H,I); DBS preparations exposed to almorexant/DMSO show a significant increase in fR (+22.7% [12.4;43.7], p < 0.01) not significantly different from that observed in absence of almorexant (+29.2% [16.4;46.4]; Figure 6C) at 25–30 min of metabolic acidosis. However, blocking OX1R/OX2R supress strengthening of respiratory response to prolonged metabolic acidosis induced by ETO (Figures 6F,G,J,K); DBS preparations exposed to almorexant/5⋅10–1 μM ETO show an increase in fR not significantly different from almorexant/DMSO exposure (+22.8% [3.9;50.4], p < 0.05 vs. +22.7% [12.4;43.7]; Figure 6C) at 25–30 min of metabolic acidosis. This increase in fR under almorexant/5⋅10–1 μM ETO exposure is significantly lower than under 5⋅10–1 μM ETO exposure alone (+68.2% [57.1;149.3], p < 0.01; Figure 6C) at 25–30 min of metabolic acidosis.
Orexin Strengthens Increase in fR Induced by Prolonged Metabolic Acidosis
In the presence of orexin at 10–2 μM, metabolic acidosis induces an increase in fR at 25–30 min of metabolic acidosis (+95.9% [74.5;102.5], p < 0.04). This increase in fR is significantly greater than under DMSO alone (+29.2% [16.4;46.4], p < 0.02; Figure 6L), and not significantly different from ETO (+68.2% [57.1;149.3]; Figure 6C).
Exciting Orexin Systems by Orexin Suppresses Strengthening of Respiratory Response to Prolonged Metabolic Acidosis Induced by Etonogestrel
Under simultaneous orexin/ETO exposure, fR is significantly increased by metabolic acidosis from 15–20 min (+19.2% [7.2;41.9], p < 0.05) compared to 25–30 min of metabolic acidosis (+30.0% [6.6;83.8], p < 0.04). At the end of metabolic acidosis exposure, increase in fR under orexin/ETO is significantly less from that observed under ETO alone (+68.2% [57.1;149.3]; p < 0.05; Figure 6L). To note this response is not significantly different from that observed under DMSO (+29.2% [16.4;46.4]; Figure 6L). Same conclusion is also observed when orexin/ETO co-exposure followed an exposure to orexin alone; DBS preparations exposed to orexin/ETO show an increase in fR induced by metabolic acidosis from 15–20 min (+20.1% [7.4;36.0], p < 0.01) that reaches (+21.6% [5.1;42.5], p < 0.04) at 25–30 min of metabolic acidosis. This increase in fR is significantly less from that observed under ETO alone (+68.2% [57.1;149.3], p < 0.04; Figure 6L), but not significantly different from that observed under orexin alone and DMSO (Figure 6L).
Blocking OX1R and OX2R by Almorexant Prevents Increase in c-fos Expression Induced by Etonogestrel Under Prolonged Metabolic Acidosis in Most of Structures Modulated by Progestin
Antagonization of orexin signaling suppresses capacity of ETO to increase c-fos expression in most of structures displaying an increase or enhanced increase in number of c-FOS positive neurons by the progestin. Indeed, in the presence of almorexant, number of c-FOS positive cells following ETO exposure is no longer statistically different from that observed under DMSO at the level of medulla oblongata in cNTS, vlNTS, mNTS, and VLM (27.97 ± 2.14 vs 22.27 ± 1.70), pons in LC, and mesensephalon in lPAG and vlPAG (Table 2). In contrast, both RPa and ROb exposed to almorexant/ETO still show a higher number of c-FOS positive cells than when exposed to almorexant/DMSO: ROb (p < 0.05), RPa (p < 0.05) (Table 2).
Finally, the proportion of orexin immunoreactive cells among population of c-FOS-positive cells in caudal hypothalamus is significantly lower following exposure to almorexant/ETO than ETO alone (2.9 [2.8;3.8] c-FOS/orexin positive cells per section vs. 7.3 [5.7;12.0] c-FOS/orexin positive cells per section, p < 0.05, respectively).
Discussion
This study focused on characterization of central mechanisms underlying the effect of ETO, a progestin of gonane family, on respiratory response to metabolic acidosis. Interest in this progestin arose from a serendipitous clinical observation suggesting desogestrel, the prodrug of ETO, may have been involved in recovery of CO2/H+ chemosensitivity by CCHS patients (
Prolonged metabolic acidosis increased fR, similar to previously described (
Origin of increase in both number of c-FOS-positive cells in VLM and fR may be caused by stimulation of CO2/H+ chemosensitive cells by metabolic acidosis. Consistent with this hypothesis, our analysis of c-fos expression suggests an increase in activity in RTN, considered as an important site of CO2/H+ chemosensitivity, especially during the neonatal period (
We showed ETO exposure shortened the latency of observing an increase in fR and strengthened the increase in fR induced by prolonged metabolic acidosis on DBS preparations, in accordance with our exploratory study (
We showed ETO induced a strengthening of respiratory response to prolonged metabolic acidosis by interacting with diencephalic, but not brainstem structures. We predict caudal hypothalamic CO2/H+-stimulated neurons are involved in ETO-induced strengthening of increase in fR, because of the existence of CO2/H+-stimulated neurons in the caudal hypothalamus (
An explanatory hypothesis for an absence of ETO effect at high concentration or when ETO at an effective dose was combined with orexin could be activation of mechanisms that obscure the response to metabolic acidosis or desensitization or internalization of OXR, already described in other conditions (
Several lines of evidence obtained in adult rat or juvenile mice have emerged showing orexin neurons are CO2/H+ chemosensitive and contribute to respiratory response to hypercapnia (Williams et al., 2007;
Of course, it cannot be overlooked data presently obtained were from central nervous system of newborn, and clinical observations in CCHS patients are in adults (
Respiratory-related brainstem structures in DBS preparations (vlNTS, VLM, LC, and vlPAG) exposed to ETO under prolonged metabolic acidosis displayed an enhanced increase in c-fos expression in same way that exposure to ETO potentiated the metabolic acidosis-dependant increase in c-fos expression. Several other respiratory-related structures (cNTS, mNTS, RPa, Rob, and lPAG) displayed a de novo increase in c-fos expression; such an increase was not observed without ETO. It is possible that at least a part of these structures was involved in the reinforcement of respiratory response to prolonged metabolic acidosis induced by ETO. In support of this hypothesis, anatomical and/or functional connections are described between these structures and VLM (
We assume enhanced activation or activation of NTS, VLM, LC, and PAG neurons relied directly or indirectly on orexin binding to OX1R and OX2R, as we did not observe ETO-induced enhanced increased and de novo increase in c-fos expression in these structures in the presence of almorexant. In contrast, both ROb, and RPa still showed an increased number of c-FOS positive cells in the presence of almorexant, suggesting ETO may act on these structures, independently of activation of orexin neurons under conditions of prolonged metabolic acidosis. Nevertheless, potential action of ETO on ROb and RPa neurons was not sufficient on its own to induce strengthening of respiratory response to CO2/H+, since we did not observe an enhancement of the increase in fR induced by prolonged metabolic acidosis in DBS preparations under almorexant and in MS preparations. The fact that despite all ETO exerts a facilitating influence on ROb and RPa neurons must be viewed in light of our recent data showing ETO significantly increases baseline fR in MS preparations of newborn mice, probably through direct activation of the serotoninergic neurons of RPa and ROb (
In conclusion, our results highlight a central mechanism of action through which gonane progestin desogestrel may have induced recovery of CO2/H+ chemosensitivity in CCHS patients. Collectively, our results obtained on ex vivo CNS preparations suggest ETO strengthens respiratory response to CO2/H+ in neonates at a small concentration range and that, its effect relies mostly on activation of orexin neurons, which activate or enhance activation of several brainstem respiratory-related structures, which in turn may exert a facilitatory influence on the CRD. Our data also suggest activation of ROb and RPa neurons by a pathway, independent of orexin signaling, that is yet to be determined. Combined with our previous work on the medullary pathway involved in the effect of ETO on resting breath (
Statements
Data availability statement
The datasets generated for this study are available on request to the corresponding author.
Ethics statement
The animal study was reviewed and approved by Charles Darwin Ethics Committee for Animal Experimentation (Ce5/2011/05; APAFIS#2210-2015100812195835v2).
Author contributions
CL contributed to conception of experiments, acquisition and analysis of electrophysiological, pharmacological and immunohistochemical data, figure formatting, data interpretation, discussion of results and implications, and writing of the manuscript. AC performed acquisition and analysis of electrophysiological and pharmacological data. BB acquired of immunohistochemical data. FC performed acquisition and analysis of electrophysiological, pharmacological and immunohistochemical data, figure formatting, discussion of results and implications. LB contributed to conception and supervision of all experiments, acquisition of funding, figure formatting, data interpretation, discussion of results and implications, and writing of the manuscript.
Funding
The work was supported by grants from French National Research Agency (ProgestVentil; ANR-15-CE17), Association Française pour le syndrome d’Ondine and Chancellerie des Universités de Paris (Legs Poix 1504).
Acknowledgments
We thank pharmaceutical company Actelion for generously supplying us with almorexant (ACT-078573, (2R)-2-{(1S)-6,7-dimethoxy-1-[2-(4-trifluoromethylphenyl)-ethyl]-3,4-dihydro-1Hisoquinolin-2-yl}-N-methyl-2-phenyl-acetamide), Professors Thomas Similowski and Christian Straus for discussing results and their significance, Dr. Isabelle Rivals for her help in carrying out statistical analyses and William Hempel (Alex Edelman & Associates) for editing the English text.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AmielJ.DubreuilV.RamanantsoaN.FortinG.GallegoJ.BrunetJ. F.et al (2009). PHOX2B in respiratory control: lessons from congenital central hypoventilation syndrome and its mouse models.Respir. Physiol. Neurobiol.168125–132. 10.1016/j.resp.2009.03.005
2
AmielJ.LaudierB.Attie-BitachT.TrangH.de PontualL.GenerB.et al (2003). Polyalanine expansion and frameshift mutations of the paired-like homeobox gene PHOX2B in congenital central hypoventilation syndrome.Nat. Genet.33459–461. 10.1038/ng1130
3
BackD. J.GrimmerS. F.ShenoyN.OrmeM. L. (1987). Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-keto-desogestrel.Contraception35619–626. 10.1016/s0010-7824(87)80021-5
4
BamfordO. S.SchuenJ. N.CarrollJ. L. (1996). Effect of nicotine exposure on postnatal ventilatory responses to hypoxia and hypercapnia.Respir. Physiol.1061–11. 10.1016/0034-5687(96)00051-5
5
BaylissD. A.CidlowskiJ. A.MillhornD. E. (1990). The stimulation of respiration by progesterone in ovariectomized cat is mediated by an estrogen-dependent hypothalamic mechanism requiring gene expression.Endocrinology126519–527. 10.1210/endo-126-1-519
6
BaylissD. A.MillhornD. E.GallmanE. A.CidlowskiJ. A. (1987). Progesterone stimulates respiration through a central nervous system steroid receptor-mediated mechanism in cat.Proc. Natl. Acad. Sci. U.S.A.847788–7792. 10.1073/pnas.84.21.7788
7
BiancardiV.BicegoK. C.AlmeidaM. C.GargaglioniL. H. (2008). Locus coeruleus noradrenergic neurons and CO2 drive to breathing.Pflugers Arch.4551119–1128. 10.1007/s00424-007-0338-8
8
Brisbare-RochC.DingemanseJ.KobersteinR.HoeverP.AissaouiH.FloresS.et al (2007). Promotion of sleep by targeting the orexin system in rats, dogs and humans.Nat. Med.13150–155. 10.1038/nm1544
9
CaoY.MatsuyamaK.FujitoY.AokiM. (2006). Involvement of medullary GABAergic and serotonergic raphe neurons in respiratory control: electrophysiological and immunohistochemical studies in rats.Neurosci. Res.56322–331. 10.1016/j.neures.2006.08.001
10
CieloC.MarcusC. L. (2014). Central hypoventilation syndromes.Sleep Med. Clin.9105–118. 10.1016/j.jsmc.2013.10.005
11
CoatesE. L.LiA.NattieE. E. (1993). Widespread sites of brain stem ventilatory chemoreceptors.J. Appl. Physiol.755–14. 10.1152/jappl.1993.75.1.5
12
ConnellyC. A.EllenbergerH. H.FeldmanJ. L. (1989). Are there serotonergic projections from raphe and retrotrapezoid nuclei to the ventral respiratory group in the rat?Neurosci. Lett.10534–40. 10.1016/0304-3940(89)90007-4
13
DalrympleM. B.JaegerW. C.EidneK. A.PflegerK. D. (2011). Temporal profiling of orexin receptor-arrestin-ubiquitin complexes reveals differences between receptor subtypes.J. Biol. Chem.28616726–16733. 10.1074/jbc.M111.223537
14
DannemanP. J.MandrellT. D. (1997). Evaluation of five agents/methods for anesthesia of neonatal rats.Lab Anim Sci.47386–395.
15
DarwinkelA.StanicD.BoothL. C.MayC. N.LawrenceA. J.YaoS. T. (2014). Distribution of orexin-1 receptor-green fluorescent protein- (OX1-GFP) expressing neurons in the mouse brain stem and pons: co-localization with tyrosine hydroxylase and neuronal nitric oxide synthase.Neuroscience278253–264. 10.1016/j.neuroscience.2014.08.027
16
DateY.UetaY.YamashitaH.YamaguchiH.MatsukuraS.KangawaK.et al (1999). Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems.Proc. Natl. Acad. Sci. U.S.A.96748–753. 10.1073/pnas.96.2.748
17
DavisS. E.SolhiedG.CastilloM.DwinellM.BrozoskiD.ForsterH. V. (2006). Postnatal developmental changes in CO2 sensitivity in rats.J. Appl. Physiol.1011097–1103. 10.1152/japplphysiol.00378.2006
18
DeanJ. B.BaylissD. A.EricksonJ. T.LawingW. L.MillhornD. E. (1990). Depolarization and stimulation of neurons in nucleus tractus solitarii by carbon dioxide does not require chemical synaptic input.Neuroscience36207–216. 10.1016/0306-4522(90)90363-9
19
DepuyS. D.KanbarR.CoatesM. B.StornettaR. L.GuyenetP. G. (2011). Control of breathing by raphe obscurus serotonergic neurons in mice.J. Neurosci.311981–1990. 10.1523/JNEUROSCI.4639-10.2011
20
DillonG. H.WaldropT. G. (1993). Responses of feline caudal hypothalamic cardiorespiratory neurons to hypoxia and hypercapnia.Exp. Brain Res.96260–272.
21
DubreuilV.RamanantsoaN.TrochetD.VaubourgV.AmielJ.GallegoJ.et al (2008). A human mutation in Phox2b causes lack of CO2 chemosensitivity, fatal central apnea, and specific loss of parafacial neurons.Proc. Natl. Acad. Sci. U.S.A.1051067–1072. 10.1073/pnas.0709115105
22
DubreuilV.Thoby-BrissonM.RalluM.PerssonK.PattynA.BirchmeierC.et al (2009). Defective respiratory rhythmogenesis and loss of central chemosensitivity in Phox2b mutants targeting retrotrapezoid nucleus neurons.J. Neurosci.2914836–14846. 10.1523/JNEUROSCI.2623-09.2009
23
EyigorO.MinbayZ.KafaI. M. (2012). Glutamate and orexin neurons.Vitam Horm.89209–222. 10.1016/B978-0-12-394623-2.00011-1
24
FeldmanJ. L.MitchellG. S.NattieE. E. (2003). Breathing: rhythmicity, plasticity, chemosensitivity.Annu. Rev. Neurosci.26239–266. 10.1146/annurev.neuro.26.041002.131103
25
GaoJ.DuanB.WangD. G.DengX. H.ZhangG. Y.XuL.et al (2005). Coupling between NMDA receptor and acid-sensing ion channel contributes to ischemic neuronal death.Neuron48635–646. 10.1016/j.neuron.2005.10.011
26
GestreauC.HeitzmannD.ThomasJ.DubreuilV.BandulikS.ReicholdM.et al (2010). Task2 potassium channels set central respiratory CO2 and O2 sensitivity.Proc. Natl. Acad. Sci. U.S.A.1072325–2330. 10.1073/pnas.0910059107
27
GuyenetP. G.BaylissD. A. (2015). Neural control of breathing and CO2 homeostasis.Neuron87946–961. 10.1016/j.neuron.2015.08.001
28
HarperR. M.KumarR.MaceyP. M.WooM. A.OgrenJ. A. (2014). Affective brain areas and sleep-disordered breathing.Prog. Brain Res.209275–293. 10.1016/B978-0-444-63274-6.00014-X
29
HornE. M.WaldropT. G. (1998). Suprapontine control of respiration.Respir. Physiol.114201–211. 10.1016/s0034-5687(98)00087-5
30
HuangS. C.DaiY. W.LeeY. H.ChiouL. C.HwangL. L. (2010). Orexins depolarize rostral ventrolateral medulla neurons and increase arterial pressure and heart rate in rats mainly via orexin 2 receptors.J. Pharmacol. Exp. Ther.334522–529. 10.1124/jpet.110.167791
31
JoubertF.Perrin-TerrinA. S.VerkaerenE.CardotP.FiammaM. N.FrugiereA.et al (2016). Desogestrel enhances ventilation in ondine patients: animal data involving serotoninergic systems.Neuropharmacology107339–350. 10.1016/j.neuropharm.2016.03.041
32
KawaiA.OnimaruH.HommaI. (2006). Mechanisms of CO2/H+ chemoreception by respiratory rhythm generator neurons in the medulla from newborn rats in vitro.J. Physiol.572(Pt 2), 525–537. 10.1113/jphysiol.2005.102533
33
KobayashiS.FujitoY.MatsuyamaK.AokiM. (2010). Raphe modulation of the pre-Botzinger complex respiratory bursts in in vitro medullary half-slice preparations of neonatal mice.J. Comp. Physiol. A Neuroethol. Sens. Neural. Behav. Physiol.196519–528. 10.1007/s00359-010-0539-z
34
KumarN. N.VelicA.SolizJ.ShiY.LiK.WangS.et al (2015). Physiology. Regulation of breathing by CO(2) requires the proton-activated receptor GPR4 in retrotrapezoid nucleus neurons.Science3481255–1260. 10.1126/science.aaa0922
35
LiA.NattieE. (2006). Catecholamine neurones in rats modulate sleep, breathing, central chemoreception and breathing variability.J. Physiol.570(Pt 2), 385–396. 10.1113/jphysiol.2005.099325
36
LiA.NattieE. (2010). Antagonism of rat orexin receptors by almorexant attenuates central chemoreception in wakefulness in the active period of the diurnal cycle.J. Physiol.588(Pt 15), 2935–2944. 10.1113/jphysiol.2010.191288
37
LiA.RoyS. H.NattieE. E. (2016). An augmented CO2 chemoreflex and overactive orexin system are linked with hypertension in young and adult spontaneously hypertensive rats.J. Physiol.5944967–4980. 10.1113/JP272199
38
LiD. C.ChinC. I. C.KatoR.WardS. L. D.KeensT. (2013). Does desogestrel improve ventilatory control in congenital central hypoventilation syndrome?Am. j. Respir. Crit. Care Med.187:A5194.
39
LiN.LiA.NattieE. (2013). Focal microdialysis of CO(2) in the perifornical-hypothalamic area increases ventilation during wakefulness but not NREM sleep.Respir. Physiol. Neurobiol.185349–355. 10.1016/j.resp.2012.09.007
40
LoiseauC.OsinskiD.JoubertF.StrausC.SimilowskiT.BodineauL. (2014). The progestin etonogestrel enhances the respiratory response to metabolic acidosis in newborn rats. Evidence for a mechanism involving supramedullary structures.Neurosci. Lett.56763–67. 10.1016/j.neulet.2014.03.040
41
LopesL. T.PatroneL. G.BicegoK. C.CoimbraN. C.GargaglioniL. H. (2012). Periaqueductal gray matter modulates the hypercapnic ventilatory response.Pflugers Arch.464155–166. 10.1007/s00424-012-1119-6
42
MallardC.VexlerZ. S. (2015). Modeling ischemia in the immature brain: how translational are animal models?Stroke463006–3011. 10.1161/strokeaha.115.007776
43
MilesR. (1983). Does low pH stimulate central chemoreceptors located near the ventral medullary surface?Brain Res.271349–353. 10.1016/0006-8993(83)90300-1
44
MulkeyD. K.StornettaR. L.WestonM. C.SimmonsJ. R.ParkerA.BaylissD. A.et al (2004). Respiratory control by ventral surface chemoreceptor neurons in rats.Nat. Neurosci.71360–1369. 10.1038/nn1357
45
MurakoshiT.SuzueT.TamaiS. (1985). A pharmacological study on respiratory rhythm in the isolated brainstem-spinal cord preparation of the newborn rat.Br. J. Pharmacol.8695–104. 10.1111/j.1476-5381.1985.tb09439.x
46
OkadaY.ChenZ.JiangW.KuwanaS.EldridgeF. L. (2002). Anatomical arrangement of hypercapnia-activated cells in the superficial ventral medulla of rats.J. Appl. Physiol.93427–439. 10.1152/japplphysiol.00620.2000
47
OkadaY.KawaiA.MuckenhoffK.ScheidP. (1998). Role of the pons in hypoxic respiratory depression in the neonatal rat.Respir. Physiol.11155–63. 10.1016/s0034-5687(97)00105-9
48
OnimaruH.HommaI. (2003). A novel functional neuron group for respiratory rhythm generation in the ventral medulla.J. Neurosci.231478–1486. 10.1523/jneurosci.23-04-01478.2003
49
OyamadaY.BallantyneD.MuckenhoffK.ScheidP. (1998). Respiration-modulated membrane potential and chemosensitivity of locus coeruleus neurones in the in vitro brainstem-spinal cord of the neonatal rat.J. Physiol.513(Pt 2), 381–398. 10.1111/j.1469-7793.1998.381bb.x
50
PagliardiniS.JanczewskiW. A.TanW.DicksonC. T.DeisserothK.FeldmanJ. L. (2011). Active expiration induced by excitation of ventral medulla in adult anesthetized rats.J. Neurosci.312895–2905. 10.1523/JNEUROSCI.5338-10.2011
51
PardridgeW. M.MietusL. J. (1979). Transport of steroid hormones through the rat blood-brain barrier. primary role of albumin-bound hormone.J. Clin. Invest.64145–154. 10.1172/jci109433
52
Park-ChungM.WuF. S.FarbD. H. (1994). 3 alpha-Hydroxy-5 beta-pregnan-20-one sulfate: a negative modulator of the NMDA-induced current in cultured neurons.Mol. Pharmacol.46146–150.
53
PaxinosG. W. C. (1998). The Rat Brain in Stereotaxic Coordinates.Cambridge, MA: Academic Press.
54
PeyronC.TigheD. K.van den PolA. N.de LeceaL.HellerH. C.SutcliffeJ. G.et al (1998). Neurons containing hypocretin (orexin) project to multiple neuronal systems.J. Neurosci.189996–10015. 10.1523/jneurosci.18-23-09996.1998
55
PtakK.YamanishiT.AungstJ.MilescuL. S.ZhangR.RichersonG. B.et al (2009). Raphe neurons stimulate respiratory circuit activity by multiple mechanisms via endogenously released serotonin and substance P.J. Neurosci.293720–3737. 10.1523/JNEUROSCI.5271-08.2009
56
RenJ.GreerJ. J. (2006). Neurosteroid modulation of respiratory rhythm in rats during the perinatal period.J. Physiol.574(Pt 2), 535–546. 10.1113/jphysiol.2006.108829
57
Ribas-SalgueiroJ. L.MatarredonaE. R.RibasJ.PasaroR. (2006). Enhanced c-Fos expression in the rostral ventral respiratory complex and rostral parapyramidal region by inhibition of the Na+/H+ exchanger type 3.Auton. Neurosci.12347–354. 10.1016/j.autneu.2006.01.022
58
RichterD. W.SpyerK. M. (2001). Studying rhythmogenesis of breathing: comparison of in vivo and in vitro models.Trends Neurosci.24464–472. 10.1016/s0166-2236(00)01867-1
59
RossC. A.RuggieroD. A.ReisD. J. (1985). Projections from the nucleus tractus solitarii to the rostral ventrolateral medulla.J. Comp. Neurol.242511–534. 10.1002/cne.902420405
60
RupprechtR.HolsboerF. (1999). Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives.Trends Neurosci.22410–416. 10.1016/s0166-2236(99)01399-5
61
RyanJ. W.WaldropT. G. (1995). Hypoxia sensitive neurons in the caudal hypothalamus project to the periaqueductal gray.Respir. Physiol.100185–194. 10.1016/0034-5687(95)00010-b
62
SchindlerA. E.CampagnoliC.DruckmannR.HuberJ.PasqualiniJ. R.SchweppeK. W.et al (2003). Classification and pharmacology of progestins.Maturitas46(Suppl. 1), S7–S16.
63
SerraA.BrozoskiD.HedinN.FranciosiR.ForsterH. V. (2001). Mortality after carotid body denervation in rats.J. Appl. Physiol.911298–1306. 10.1152/jappl.2001.91.3.1298
64
ShahidI. Z.RahmanA. A.PilowskyP. M. (2012). Orexin and central regulation of cardiorespiratory system.Vitam Horm.89159–184. 10.1016/B978-0-12-394623-2.00009-3
65
SlatkovskaL.JensenD.DaviesG. A.WolfeL. A. (2006). Phasic menstrual cycle effects on the control of breathing in healthy women.Respir. Physiol. Neurobiol.154379–388. 10.1016/j.resp.2006.01.011
66
SongN.ZhangG.GengW.LiuZ.JinW.LiL.et al (2012). Acid sensing ion channel 1 in lateral hypothalamus contributes to breathing control.PLoS One7:e39982. 10.1371/journal.pone.0039982
67
SritippayawanS.HamutcuR.KunS. S.NerZ.PonceM.KeensT. G. (2002). Mother-daughter transmission of congenital central hypoventilation syndrome.Am. J. Respir. Crit. Care Med.166367–369. 10.1164/rccm.2112087
68
SteiningerT. L.KilduffT. S.BehanM.BencaR. M.LandryC. F. (2004). Comparison of hypocretin/orexin and melanin-concentrating hormone neurons and axonal projections in the embryonic and postnatal rat brain.J. Chem. Neuroanat.27165–181. 10.1016/j.jchemneu.2004.02.007
69
StrausC.TrangH.BecqueminM. H.TouraineP.SimilowskiT. (2010). Chemosensitivity recovery in Ondine’s curse syndrome under treatment with desogestrel.Respir. Physiol. Neurobiol.171171–174. 10.1016/j.resp.2010.03.015
70
SugitaT.SakurabaS.KakuY.YoshidaK.ArisakaH.KuwanaS. (2014). Orexin induces excitation of respiratory neuronal network in isolated brainstem spinal cord of neonatal rat.Respir. Physiol. Neurobiol.200105–109. 10.1016/j.resp.2014.06.006
71
SunanagaJ.DengB. S.ZhangW.KanmuraY.KuwakiT. (2009). CO2 activates orexin-containing neurons in mice.Respir. Physiol. Neurobiol.166184–186. 10.1016/j.resp.2009.03.006
72
SuzueT. (1984). Respiratory rhythm generation in the in vitro brain stem-spinal cord preparation of the neonatal rat.J. Physiol.354173–183. 10.1113/jphysiol.1984.sp015370
73
UmezawaN.ArisakaH.SakurabaS.SugitaT.MatsumotoA.KakuY.et al (2015). Orexin-B antagonized respiratory depression induced by sevoflurane, propofol, and remifentanil in isolated brainstem-spinal cords of neonatal rats.Respir. Physiol. Neurobiol.20561–65. 10.1016/j.resp.2014.10.013
74
Van Den PolA. N.PatryloP. R.GhoshP. K.GaoX. B. (2001). Lateral hypothalamus: early developmental expression and response to hypocretin (orexin).J. Comp. Neurol.433349–363. 10.1002/cne.1144
75
VerhoevenC. H.KrebbersS. F.WagenaarsG. N.VosR. M. (1998). In vitro and in vivo metabolism of desogestrel in several species.Drug Metab. Dispos26927–936.
76
ViemariJ. C.BevengutM.BurnetH.CoulonP.PequignotJ. M.TiveronM. C.et al (2004). Phox2a gene, A6 neurons, and noradrenaline are essential for development of normal respiratory rhythm in mice.J. Neurosci.24928–937. 10.1523/jneurosci.3065-03.2004
77
VoituronN.FrugiereA.ChampagnatJ.BodineauL. (2006). Hypoxia-sensing properties of the newborn rat ventral medullary surface in vitro.J. Physiol.577(Pt 1), 55–68. 10.1113/jphysiol.2006.111765
78
VoituronN.FrugiereA.GrosF.MacronJ. M.BodineauL. (2005). Diencephalic and mesencephalic influences on ponto-medullary respiratory control in normoxic and hypoxic conditions: an in vitro study on central nervous system preparations from newborn rat.Neuroscience132843–854. 10.1016/j.neuroscience.2004.12.011
79
Weese-MayerD. E.Berry-KravisE. M.CeccheriniI.KeensT. G.LoghmaneeD. A.TrangH. (2010). An official ATS clinical policy statement: congenital central hypoventilation syndrome: genetic basis, diagnosis, and management.Am. J. Respir. Crit. Care Med.181626–644. 10.1164/rccm.200807-1069ST
80
Weese-MayerD. E.SilvestriJ. M.MenziesL. J.Morrow-KennyA. S.HuntC. E.HauptmanS. A. (1992). central hypoventilation syndrome: diagnosis, management, and long-term outcome in thirty-two children.J. Pediatr.120381–387. 10.1016/s0022-3476(05)80901-1
81
WickstromR.HokfeltT.LagercrantzH. (2002). Development of CO(2)-response in the early newborn period in rat.Respir. Physiol. Neurobiol.132145–158. 10.1016/s1569-9048(02)00076-9
82
WilliamsR. H.JensenL. T.VerkhratskyA.FuggerL.BurdakovD. (2007). Control of hypothalamic orexin neurons by acid and CO2.Proc. Natl. Acad. Sci. U.S.A.10410685–10690. 10.1073/pnas.0702676104
83
YamamotoY.UetaY.HaraY.SerinoR.NomuraM.ShibuyaI.et al (2000). Postnatal development of orexin/hypocretin in rats.Brain Res. Mol. Brain Res.78108–119. 10.1016/s0169-328x(00)00080-2
84
YoungJ. K.WuM.ManayeK. F.KcP.AllardJ. S.MackS. O.et al (2005). Orexin stimulates breathing via medullary and spinal pathways.J. Appl. Physiol.981387–1395. 10.1152/japplphysiol.00914.2004
85
ZhangW.HaywardL. F.DavenportP. W. (2005). Respiratory muscle responses elicited by dorsal periaqueductal gray stimulation in rats.Am. J. Physiol. Regul. Integr. Comp. Physiol.289R1338–R1347.
86
ZhengH.PattersonL. M.BerthoudH. R. (2005). Orexin-A projections to the caudal medulla and orexin-induced c-Fos expression, food intake, and autonomic function.J. Comp. Neurol.485127–142. 10.1002/cne.20515
Summary
Keywords
CO2/H+ chemosensitivity, congenital central hypoventilation syndrome, etonogestrel, ex vivo central nervous system preparation, orexin, progestin
Citation
Loiseau C, Casciato A, Barka B, Cayetanot F and Bodineau L (2019) Orexin Neurons Contribute to Central Modulation of Respiratory Drive by Progestins on ex vivo Newborn Rodent Preparations. Front. Physiol. 10:1200. doi: 10.3389/fphys.2019.01200
Received
07 June 2019
Accepted
03 September 2019
Published
27 September 2019
Volume
10 - 2019
Edited by
Gregory D. Funk, University of Alberta, Canada
Reviewed by
Robert Timothy Richard Huckstepp, University of Warwick, United Kingdom; Daniel K. Mulkey, University of Connecticut, United States; Aihua Li, Dartmouth College, United States
Updates

Check for updates
Copyright
© 2019 Loiseau, Casciato, Barka, Cayetanot and Bodineau.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Laurence Bodineau, laurence.bodineau@sorbonne-universite.fr
This article was submitted to Respiratory Physiology, a section of the journal Frontiers in Physiology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.